ObjectiveTo investigate the effect of microRNA507 （miR507） on the proliferation， apoptosis， migration and PI3K／Akt signaling pathway of hepatoma cells and analyze the targeting regulation of miR507 on vascular endothelial growth factor C （VEGFC）. 
MethodsQuantitative realtime polymerase chain reaction （QPCR） was used to detect the levels of miR507 and VEGFC mRNA in the cancer tissues and paracancerous tissues of 90 patients with hepatoma cancer from January 2014 to March 2017. Human hepatoma cells HepG2 were transfected with miR507 mimics （overexpressing group） or negative control （NC group） by liposome method. QPCR was used to detect the miR507 level after 48 htransfection. MTT method was used to compare the cell proliferation at different treatment times （0， 12， 24， 48 h）. Flow cytometry with Annexin ⅤFITC／PI staining was used to detect the cell apoptosis， and the scratch test was used to compare the migration of each group. QPCR and Western blotting were employed to detect the mRNA and protein levels of VEGFC and PI3K／Akt signal pathwaysrelated genes including pAkt and pPI3K. Dual luciferase reporter gene test was used to verify the target relationship and binding site between miR507 and target gene VEGFC. 
ResultsQPCR detection showed that the level of miR507 in hepatoma cancer tissues was 0672±0089， lower than 1142±0136 in paracancerous tissues and level of VEGFC mRNA in hepatoma cancer tissues was 1482±0156， higher than 1021±0087 in paracancerous tissues （P＜005）. Compared with the NC group and the control group， the proliferative activity of HepG2 cells in the overexpressing group was significantly decreased after transfection of 2448 h （P＜001）. The apoptotic rate of HepG2 cells in overexpressing group was （1726±196）％， higher than （785±087）％ of NC group and （813±069）％ of control group （P＜005）. The healing rate of HepG2 cells in overexpressing group was （3965±487）％， lower than （5818±273）％ in NC group and （5724±317）％ in control group （P＜005）. The protein and mRNA levels of pAkt， pPI3K and VEGFC in the overexpression group were lower than those in the NC group and the control group （P＜005）. The double luciferase reporter gene experiment proved that VEGFC was a direct target of miR507. 
ConclusionMiR507 may regulate HepG2 cells proliferation， apoptosis and migration through targeting VEGFC of PI3K／Akt signal pathway， and serve as a potential therapeutic strategy in hepatoma cancer.

ObjectiveTo investigate the effect of macrophage migration inhibitory factor （MIF）targeting small interference RNA （siRNA） on proliferation and apoptosis of gastric cancer SGC7901 cells. 
MethodsSGC7901 cells at logarithmic growth phase were transfected with human MIF siRNA （siMIF group） or negative control sequence （NC group） by liposome method. Western blotting was used to detect the expression of MIF protein at 48 h after transfection. MTT method was used to observe the proliferation at 24， 48 and 72 h after transfection. The apoptotic rate was detected by flow cytometry at 72 h after transfection. Western blotting was used to detect the expression of apoptosisrelated proteins Bcl2 and Bax. 
ResultsAfter transfection for 48 h， the relative expression of MIF protein in siMIF group was 0321±0104， lower than 1078±0212 in NC group， and the difference was statistically significant （P＜005）. The proliferative rates of siMIF group were lower than those of NC group at 4872 h after transfection， and the difference was statistically significant （P＜005）. After transfection of MIF siRNA for 72 h， the apoptotic rate of siMIF group was （235±36）％， higher than （47±17）％ of NC group， and the difference was statistically significant （P＜005）. The relative expression of Bcl2 in siMIF group was 0663±0209， lower than 1129±0178 in NC group， and the relative expression of Bax in siMIF group was 0981±0225， higher than 0587±0254 in NC group， and the above difference was statistically significant （P＜005）. 
ConclusionSiRNA targeting MIF can reduce the expression of MIF protein in SGC7901 cells， inhibit the proliferation and promote apoptosis of SGC7901 cells， and it has a certain prospect in the target therapy of gastric cancer.

ObjectiveTo investigate the expression of potassium inwardlyrectifying channel subfamily J member 15 （KCNJ15） in lung adenocarcinoma tissues and its effect on proliferation and migration of lung adenocarcinoma A549 cells. 
MethodsA total of 117 lung cancer tissues and 50 paracancerous tissues were collected from July 2006 to October 2015 in our hospital. The mRNA levels of KCNJ15 in the above tissues were detected by realtime quantitative PCR， and the relationship between the mRNA level of KCNJ15 in the lung adenocarcinoma tissues and the clinicopathological parameters （sex， age， tumor size， clinical stage， tumor location， lymph node metastasis and pathological grade） was analyzed. The prognosis of different KCNJ15 mRNA levels was analyzed according to the followup data. The overexpression vector of KCNJ15 was constructed and transfected into A549 cells. The function of KCNJ15 gene on proliferation and migration of A549 cells was analyzed by CCK8 and Transwell assay. 
ResultsThe mRNA level of KCNJ15 gene in lung adenocarcinoma tissues was significantly lower than that of paracancerous tissues （P＜005）. The expression of KCNJ15 gene was related to the size and clinical stage of the lung adenocarcinoma （P＜005）， but not related to age， pathological grade， sex， lymph node metastasis and tumor location （P＞005）. The overall survival of the lung adenocarcinoma patients with high expression of KCNJ15 was longer than patients with low expression. The results of the acquired functional experiment showed that the overexpression of KCNJ15 gene could inhibit the proliferation and migration of lung adenocarcinoma cells. 
ConclusionThe expression of KCNJ15 gene in lung adenocarcinoma is obviously decreased. Its expression is related to the size and clinical stage of lung adenocarcinoma. It is an important prognostic marker in the survival of the patients with lung adenocarcinoma， and can be used as a potential new target for the clinical treatment of lung adenocarcinoma.

ObjectiveTo explore the expression of microRNA155 （miR155） in cervical cancer tissues and its effect on proliferation and invasion of cervical cancer cells. 
MethodsWe collected 76 cases of cervical cancer tissues， 63 cases of normal cervical tissue and 84 cases of cervical intraepithelial neoplasia tissues （22 cases of CIN Ⅰ， 29 cases of CIN Ⅱ and 33 cases of CIN Ⅲ） from May 2014 to December 2016 in our hospital. The miR155 levels in the above tissues were detected by realtime quantitative PCR （QPCR）， and the relationship between the miR155 level and the clinicopathological parameters of cervical cancer （age， FIGO staging， tumor size， histological grade， pathological type， vascular invasion and lymph node metastasis） was analyzed. HeLa cells were transfected with miR155 inhibitor （transfection group） and negative control （control group）， and the miR155 level of each group after transfection of 48 h was detected by QPCR. The proliferative rate and the cell number of penetrating membrane were detected by MTT and Transwell invasiveness test， respectively. 
ResultsQPCR detection showed that the miR155 level in cervical cancer tissues was 4270±1901， higher than that in normal cervical tissues and CIN tissues （P＜005）. The level of miR155 was not related to age， histological grade and pathological type of cervical cancer （P＞005）， but it was related to FIGO staging， tumor size， vascular invasion and lymph node metastasis （P＜005）. The miR155 level of cervical cancer cells transfected with miR155 inhibitor at 48 h was 0265±0034， lower than 1027±0158 of the control group （P＜005）. Compared with the control group， the proliferative rate and the number of penetrating membrane in the transfection group were lower （P＜005）. 
ConclusionMiR155 is highly expressed in cervical cancer tissues， and is associated with clinical stage， vascular invasion and lymph node metastasis. MiR155 is involved in the development of cervical cancer. Downregulating the level of miR155 can inhibit the proliferation and invasion process， and has a certain value in the prevention and treatment of cervical cancer.

ObjectiveTo investigate the serum microRNA30 （miR30） level in gastric cancer patients and analyze its relationship with clinicopathological features and prognosis. 
MethodsThe serum samples of 108 patients with gastric cancer from March 2014 to May 2017 and 100 health examiners in the same period were collected， and the miR30 levels in the above samples were detected by realtime quantitative PCR （QPCR）. The difference of miR30 level between the patients with gastric cancer and the health examiners were compared. The values of the miR30 level were divided into the lowexpression group （＜average value） and the highexpression group （＞average value）. The relationship between miR30 level and clinicopathological parameters （gender， age， lymph node metastasis， tumor size， TNM staging， depth of infiltration， Lauren classification and differentiation） was analyzed， and the prognosis of different serum miR30 levels was compared according to the followup data. 
ResultsThe serum miR30 level of gastric cancer patients was 0624±0075， lower than 1028±0094 of the control group， and the difference was statistically significant （P＜005）. The results of ROC curve analysis showed that the area under the curve of miR30 for diagnosis of gastric cancer was 0802 （95％CI： 07420861， P＜0001）. When the diagnostic threshold was 0798， the sensitivity was 759％ and the specificity was 76％. Serum miR30 levels in patients with gastric cancer were not related to sex， age， depth of infiltration and Lauren classification， but related to lymph node metastasis， tumor size， TNM staging and degree of differentiation （P＜005）. The low expression rates of patients with lymph node metastasis， tumor size more than 5 cm， TNM ⅢⅣ and low differentiation were 632％ （48／76）， 726％ （45／62）， 923％ （36／39） and 681％ （32／47）， higher than 375％ （12／32）， 326％ （15／46）， 348％ （24／69） and 459％ （28／61） of lymph nodes without metastasis， tumor size＜5 cm， TNM ⅠⅡ and middlehigh differentiation （P＜005）. The median overall survival of miR30 lowexpression group was 230 months， shorter than 360 months of highexpression group （P＜005）. 
ConclusionMiR30 is lowly expressed in the serum of patients with gastric cancer， and is involved in the development of gastric cancer and the prognosis of patients with low serum miR30 level is poor. It has the potential as a molecular screening and prognostic marker for gastric cancer.

ObjectiveTo investigate the predictive value of βcatenin and Ecadherin in patients with early gastric cancer （stage T12N0） undergoing radical resection. 
MethodsThree hundred and sixtysix patients with early gastric cancer who underwent surgical resection from July 2012 to June 2014 in Suining central hospital were selected. The recurrence of the patients was followed up. Immunohistochemical staining was used to detect the expression of βcatenin and Ecadherin in gastric cancer tissues and their relationship with the clinicopathological characteristics of gastric cancer. Multivariate Logistic regression analysis was used to analyze the independent risk factors for recurrence. 
ResultsA total of 42 patients relapsed during the followup period. There was a significant difference in pathological type， depth of invasion， degree of differentiation， education level and place of residence between recurrent and non recurrent patients （P＜005）. Of the 366 patients， 221 had high expression of βcatenin and high expression of Ecadherin in 150 cases， and the expression of βcatenin and Ecadherin was closely related to the depth of infiltration， degree of differentiation and recurrence （P＜005）. Multivariate Logistic regression analysis showed that invasion depth， abnormal expression of βcatenin and Ecadherin were independent factors for postoperative recurrence of gastric cancer （P＜005）. There was no correlation between the expression of βcatenin and Ecadherin in recurrent gastric cancer （r=-0033， P=0836）. 
ConclusionAbnormal expression of βcatenin and Ecadherin can be used as predictors of postoperative recurrence in early gastric cancer patients， and it is helpful for screening highrisk patients with postoperative recurrence.

ObjectiveTo investigate the expression of high mobility group box A2 （HMGA2） in hepatocellular carcinoma （HCC） tissues as well as its relationship with clinicopathological parameters and prognosis. 
MethodsIn this study， 120 cases of surgically resected HCC tissues， paracancerous tissues and normal liver tissues were collected from January 2011 to December 2012. The expression of HMGA2 in the above tissues was detected by immunohistochemical SP. The expression of HMGA2 and HCC clinicopathological parameters （sex， age， differentiation， TNM staging， hepatic hilar lymph node metastasis， number of tumor foci， tumor size and intrahepatic metastasis） were analyzed. The prognosis of HCC patients with different HMGA2 expression was analyzed according to the followup data. 
ResultsImmunohistochemistry showed that the nuclei with HMGA2 expression in cells were brownish yellow or tan. The positive rate of HMGA2 in HCC tissue was 6417％ （77／120）， higher than 834％ （10／120） of paracancerous tissues and 417％ （5／120） of normal tissue （P＜005）. There was no significant difference in the positive rates of HMGA2 between paracancerous tissues and normal tissues （P＞005）. The expression of HMGA2 was related to the degree of differentiation of HCC， TNM staging， hepatic hilar lymph node metastasis， number of tumor foci， tumor size and intrahepatic metastasis （P＜005）， but not related to sex and age （P＞005）. The median overall survival （OS） were 135 months for patients with HMGA2 positive expression and ＞600 months for patients with HMGA2 negative expression. Patients with HMGA2 negative expression had a longer median OS （P＜005）. The results of single factor analysis showed that HMGA2 expression， TNM staging， intrahepatic metastasis， hilar lymph node metastasis， number of tumor foci， tumor size and degree of differentiation were related to OS of HCC patients. Multivariate analysis of Cox regression showed that HMGA2 expression was an independent risk factor for HCC prognosis （HR=2516， 95％CI： 16433855）. 
ConclusionThe expression of HMGA2 protein in HCC tissue is elevated， and it participates in the development of HCC. The prognosis of HMGA2 positive expression is poor. This protein may be a potential prognostic indicator of HCC.

ObjectiveTo investigate the expression of the aurora kinase B （AURKB） gene in the bladder cancer tissues in the NCBI Gene Expression Omnibus （GEO） database and its relationship with the clinicopathological features and prognosis of bladder cancer. 
MethodsGEO datasets were collected and expression profile of AURKB and clinicopathological parameters of bladder cancer tissues were download. The relationship between the AURKB expression and the clinicopathological parameters of bladder cancer （sex， age， invasiveness， T staging， N staging， M staging and disease classification） as well as its relationship with recurrence， metastasis and prognosis were analyzed. The genes regulated by AURKB were analyzed by gene enrichment analysis （GSEA）. 
ResultsThe expression level of AURKB in bladder cancer tissues was 9621±0085， higher than 7691± 0059 of normal bladder tissues， and the difference was statistically significant （P＜005）. The expression of AURKB in bladder cancer was related to sex， invasiveness， T staging， disease classification and progression （P＜005）， not related to age， N staging， M staging and recurrence （P＞005）. The 5year overall survival rate and 5year tumor specific survival rate in the highexpression group of AURKB were 52226％ and 70256％， lower than 70112％ and 90687％ in the lowexpression group， and the difference was statistically significant （P＜005）. GSEA results showed that AURKB highexpression samples enriched the mitosis， E2F transcription factors， G2M checkpoints， MYC signaling pathways， unfolded protein responses and mitotic spindle related genes. 
ConclusionAURKB was highly expressed in bladder cancer and could be considered as a potential marker and target in the diagnosis and treatment of bladder cancer.

ObjectiveTo investigate the efficacy of different regimens in patients with anaplasticlymphoma kinase （ALK） fusion genepositive pulmonary adenocarcinoma of a cquired crizotinib resistance. 
MethodsFrom January 2014 to October 2017， 65 patients with advanced ALK fusion genepositive pulmonary adenocarcinoma of acquired crizotinib resistance in our hospital were enrolled. According to the treatment regimes， 13 cases received ALK inhibitors and remaining 52 cases received systemic chemotherapy， including 23 cases of pemetrexed plus platinum， 10 cases of paclitaxel plus platinum， 3 cases of vinorelbine and platinum， 5 cases of gemcitabine and platinum， 5 cases of pemetrexed alone and 6 cases of docetaxel alone. After 2 cycles， the efficacy and adverse reactions were evaluated by RECIST 11 and NCICTC 40， and the prognosis of different treatment schemes was analyzed according to the followup data. 
ResultsAll patients were evaluable for efficacy with the objective response rate （ORR） of 462％ and the disease control rate （DCR） of 738％. Patints receiving the second generation of ALK inhibitor showed better RR than cytotoxic drugs （769％ vs. 385％， P=0013）. For chemotherapy group， pemetrexedcontained regimens had better RR than nonpemetrexed regimens （536％ vs. 208％， P=0016）， and platinumcontained regimens were better than monotherapy in DCR （805％ vs.364％，P=0013）. The progression free survival（PFS）and overall survival （OS） of all patients were 40 months（95％CI： 3248）and 190 months（95％CI： 174206）, respectively. The second generation of ALK inhibitor was better than cytotoxic drugs for PFS （100 months vs. 40 months，P=0003） and OS （250 months vs.185 months， P=0012）. ECOG 01 （195 months vs.170 months，P=0004） and clinical stage ⅢB were favorite factors for OS （265 months vs. 185 months， P=0046） comparing with ECOG 2 and stage Ⅳ， respectively. 
ConclusionThe second generation of ALK inhibitor presented stronger efficacy in ALKfusiongene positve pulmonary adenocarcinoma patients after the failure of crizotinib. ECOG 01 and phase ⅢB patients had longer OS.

ObjectiveTo investigate the efficacy and safety of chidamide combined with paclitaxel liposome in the treatment of advanced breast cancer with negative HER2 expression. 
MethodsA total of 41 patients with advanced HER2 negative breast cancer from May 2017 to November 2017， who failed in 2 regimens of chemotherapy were enrolled and randomly divided into observation group （n=20） and control group （n=21）. Patients in observation group were given chidamide tablets （30 mg oral administration， twice per week for 2 months） and paclitaxel liposome （175 mg／m2 iv， 21 days was a cycle for 3 cycles）. In addition to paclitaxel liposome, patients in control group were given placebo （30 mg oral administration， twice per week for 2 months）. Response rate， disease control rate and progressionfree survival were analyzed. 
ResultsAll patients were evaluable for the efficacy. In observation group， there were 5 cases of CR， 7 cases of PR， 5 cases of SD and 3 cases of PD. RR was 600％ and DCR was 850％. In control group， there were 3 cases of CR， 3 cases of PR， 5 cases of SD and 10 cases of PD. RR was 286％ and DCR was 524％. The RR and DCR in observation group were higher than those in control group （P＜005）. The median PFS was 52 months in observation group， higher than 31 months in control group （P＜005）. The main adverse reactions were gastrointestinal reactions and bone marrow suppression， mainly in grade 12. The incidences of leukopenia， thrombocytopenia and nausea／vomiting were higher in observation group than in control group （P＜005）. 
ConclusionChidamide combined with paclitaxel liposome for advanced breast cancer with negative HER2 expression has good efficacy and the adverse effects are tolerable.

ObjectiveTo investigate the clinical efficacy and safety of modified VDLP （vincristine+daunorubicin+Lasparaginase+prednisone） regimen in the initial treatment of elderly patients with acute lymphoblastic leukemia （ALL）. 
MethodsFrom January 2013 to March 2015， 82 cases of elderly patients with newly diagnosed ALL in our hospital were randomly divided into observation group and control group， with 41 cases in each group. The observation group was treated with modified VDLP regimen and the control group was treated with traditional VDLP regimen with 28 days a cycle. After 2 cycles， the efficacy was evaluated and the side effects were evaluated with the NCICTCAE 4 version. The median overall survival （OS） and diseasefree survival （DFS） were compared in both groups according to the followup data. 
ResultsAll the 82 patients were evaluable for response. The complete remission rate， response rate and disease control rate of the observation group were 610％， 805％ and 976％， similar with 634％， 854％ and 100％ of the control group （P＞005）. The time to reach complete remission in the observation group was （2334±664）d， similar with （2145±602）d of the control group （P＜005）. The median OS of observation group and control group were 130 months and 120 months， and the median DFS was 75 months and 83 months （P＞005）. The incidence of bone marrow suppression in the observation group was significantly lighter than that in the control group， and the recovery time of bone marrow suppression in the observation group was （943±181）d， similar with （1239±252）d of the control group， and the difference was statistically significant （P＜005）. No significant difference was observed on alimentary tract reaction， alopecia， oral ulcers， hemogram abnormalities， cardiac toxicity， hepatotoxicity and nephrotoxicity between both groups （P＞005）. 
ConclusionThe modified VDLP regimen for the treatment of ALL in the first treatment of the elderly can obtain the shortterm effect equivalent to the traditional VDLP， but the myelosuppression is lighter and faster， which is more suitable for the induction chemotherapy of the elderly patients with ALL.

Department of Gastrointestinal Surgery， the Affiliated Shanghai Shuguang Hospital of Shanghai University of Traditional Chinese MedicineObjectiveTo compare the application effect of right laparoscope site versus central laparoscope site on clearing peripheral lymph node of inferior mesenteric arterial root in laparoscopic radical resection of rectal cancer. 
MethodsThe clinical data of 25 patients underwent laparoscopic radical resection of rectal cancer between January 2017 and May 2017 at the Affiliated Shanghai Shuguang Hospital of Shanghai University of Traditional Chinese Medicine were analyzed retrospectively. The right laparoscope site （laparoscope inserted through the right superior trocar） and central laparoscope site（laparoscope inserted through the superior umbilical trocar） were applied respectively when the peripheral lymph nodes of inferior mesenteric arterial root were dissected. There were 13 cases in the right laparoscope site group and 12 cases in the central laparoscope site group. The exposure effect of surgical field， the operation time， the time from the first incision on the mesentery to accomplish the D3 lymph node dissection， the blood loss， the number of dissected lymph nodes， the conversion rate， the postoperative hospital stay and the early postoperative complications were compared between both groups. All the operations were performed by the same surgical team. 
ResultsThe right laparoscope site was easier to expose the inferior mesenteric artery and nerve. There was no conversion. The mean time from the first incision on the mesentery to accomplish the D3 lymph node dissection were （280±59）min and（331±61）min for the right laparoscope site group and the central laparoscope site group， and there was statistically significant difference（P=0045）. The mean operation time were （1403±167）min and （1464±169）min， the mean blood loss were （596±176）ml and （633±144）ml， the mean numbers of dissected lymph nodes were 184±38 and 162±31， the postoperative hospital stay were （82±22） days and （83±21）days， and the early postoperative complication rates were 77％（1/13） and 167％（2/12）， with no statistically significant differences between both groups（P＞005）. 
ConclusionThe right laparoscope site has advantages for exposure of surgical field， lymph node dissection of inferior mesenteric arterial root， preservation of branches of inferior mesenteric artery and protection of inferior mesenteric nerve plexus.

ObjectiveTo evaluate the value of CT perfusion parameters on the radiotherapy sensitivity of cervical cancer. 
MethodsFrom February 2014 to July 2016， 120 patients with cervical cancer were enrolled. All the patients were given CT perfusion scanning to caculate the related parameters including blood flow（BF）, blood volume（BV）, mean transit time （MTT） and permeability surface（PS） and intensity modulated radiation therapy. The pelvic irradiation was 1820 Gy／f， 56 times／week， and the total dose was 4045 Gy. The curafive effect was evaluated after 4 weeks of radiotherapy. Factors influencing radiotherapy sensitivity were analyzed by Logistic regression model. 
ResultsOne hundred and twenty patients were completed the radiotherapy. There were complete remission in 34 patients， partial remission in 46 patients， stable disease in 20 patients and disease progression in 20 patients. The radiotherapy sensitivity was 667％（80/120）. Age， body mass index， tumor size， pathological type， FIGO staging and differentiation had no difference between sensitive group and insensitive group （P＞005）. But lymph node metastasis had difference between the two groups （P＜005）. The value of BF in sensitive group was significantly lower than that of insensitive group［（5922±1630）ml／（min·100 g） vs.（7204±1294）ml／（min·100 g）］， while the values of BV［（1214±281）ml／100 g vs.（568±193）ml／100 g］， MTT［（1172±448）s vs.（1034±622）s］ and PS［（2056±852）ml／（min·100 g） vs.（910±184）ml／（min·100 g）］ were significantly higher than those in insensitive group （P＜005）. Logistic regression analysis showed that BV was independent factor influencing radiotherapy sensitivity （P＜005）. 
ConclusionCT perfusion parameters of cervical cancer can evaluate and reflect radiotherapy sensitivity. BV is the main factor influencing radiotherapy sensitivity.

ObjectiveTo compare the clinical application of automatic biopsy needle and semiautomatic biopsy needle under CT guided lung biopsy. 
MethodsTwo hundred and fortytwo cases of percutaneous lung biopsy under CT guidance from March 2015 to October 2016 were performed in our hospital. Among them， 157 cases were performed with automatic biopsy needle （automatic group）， and 85 cases with semiautomatic biopsy needle （semiautomatic group）. The puncture success rate， sufficient specimen rate， diagnostic efficacy （accuracy， sensitivity and specificity） and the incidence of common complications were compared between both groups. 
ResultsThe puncture success rates were 1000％ in both groups. The sufficient specimen rate of the automatic group was 1000％ （157／157）， higher than 953％ （81／85） of the semi automatic group （P＜005）. The specificity and accuracy of the automatic group were 917％ （22／24） and （154／157）， higher than 917％ （22／24） and 981％ （154／157） of semiautomatic group （P＜005）. However， the sensitivity was 992％ （132／133） and 944％ （67／71） in the automatic group and the semiautomatic group （P＞005）. The incidence of needle bleeding was 338％ in automatic group， higher than 212％ of the semiautomatic group （P＜005）. There was no significant difference between incidences of pneumothorax， hemothorax， blood in phlegm， puncturerelated infection， air embolism and pleural reaction in both groups （P＞005）. 
ConclusionIn the operation of CT guided percutaneous lung mass puncture biopsy， two kinds of needle biopsy needles have the advantages and disadvantages， and only the applicable range is different. The automatic biopsy needle is sufficient with higher diagnostic accuracy and specificity. The semiautomatic needle biopsy needle has little risk of bleeding.

ObjectiveTo investigate the clinicopathological features of six cases of thymoma with lung metastases and the histological types， diagnosis， treatment and prognosis for this disease. 
MethodsFrom January 2009 to December 2017, the clinicopathological data of 6 cases of thymoma metastases to lung tissues were collected. The histomorphology was observed under light microscope and the differential diagnosis was made by immunohistochemistry. The clinical manifestations， histomorphological features， immunohistochemical characteristics， treatment and prognosis were analyzed. 
ResultsSix cases of thymoma with lung metastases were detected， aged from 23 to 75， 3 males and 3 females， with chest tightness and cough as initial symptom. All patients underwent surgical treatment， including excision of thymoma and lung lobe. The histological types included six cases of type B1 and B2. The pathological diagnosis for these lung metastases were also type B1 and B2. Immunohistochemistry staining showed CK（+）， CK19（+）， CD3 （+）， TdT （+）， CD99（+）， EMA（+）， CD5 （+）， p53 （+）， p63（+）， CD117（-） and Ki67 positive cells （20％60％）. No adjuvant therapy was performed in one case， radiotherapy were performed in two cases and both radiotherapy and chemotherapy were performed in three cases. All cases survived up to present. 
ConclusionAny type of thymoma might recur and develop distant metastases， requiring longterm followup. The metastases should be completely excised to achieve longterm survival.

The intestinal microflora is composed of symbiotic bacteria and other microorganisms living in the intestinal epithelium of the host. They influence a lot of physiological functions， including homeostasis maintenance of intestinal epithelial barrier and regulations of metabolism， inflammation and immunity. Moreover， intestinal microflora is also involved in the cancer occurrence， progression and metastasis. Intestinal microflora can affect the bodys response to cancer therapies and sensitivity to side effects. In the treatment of cancer， intestinal microflora is closely related to surgery， chemotherapy， radiotherapy and immunotherapy， and it may become one of the frontiers of precise medical treatment and personalized medical treatment. This article reviews the progress of intestinal microflora in cancer therapy.

In the human genome，there are a large number of long noncoding RNAs（lincRNAs）， and they regulate gene expression at various levels and are closely related to the development of many disease. Regulator of reprogramming long noncoding RNA（lincRNA ROR）is a newly discovered lincRNA which plays an important role in the formation of pluripotent stem cells， DNA damage， oxidative stress etc. A number of studies have shown that lincRNA ROR plays an important role in the occurence， development and treatment of tumor. This paper reviews the expression of lincRNA ROR in various tumors and the mechanism of its action in the development of tumor.

Breast cancer is a common malignant tumor in women. The clinical value of circulating tumor cell （CTCs） in breast cancer has become one of the focuses in recent years. There are many CTCs detection methods at present leading to huge heterogeneity which limits the widely use of research data. Nowadays， the ‘golden standard’ of CTCs detection method is still the commercial detection system named CELLSEARCH and most of the clinical studies have adopted this system. This paper will only summarize the clinical study of breast cancer CTCs based on CELLSEARCH system with the heterogeneity caused by methodological inconsistencies being avoided.